Patents by Inventor Rosanne M. Crooke

Rosanne M. Crooke has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ANTISENSE MODULATION OF CHOLESTERYL ESTER TRANSFER PROTEIN EXPRESSION
    Publication number: 20120022133
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of cholesteryl ester transfer protein. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding cholesteryl ester transfer protein. Methods of using these compounds for modulation of cholesteryl ester transfer protein expression and for treatment of diseases associated with expression of cholesteryl ester transfer protein are provided.
    Type: Application
    Filed: April 7, 2011
    Publication date: January 26, 2012
    Applicant: Isis Pharmaceuticals, Inc.
    Inventors: Rosanne M. Crooke, Mark J. Graham, Pamela Nero, Edward Wancewicz
  • Methods for treating hypercholesterolemia
    Patent number: 8093222
    Abstract: Disclosed herein are antisense compounds and methods for decreasing LDL-C in an individual having elevated LDL-C. Additionally disclosed are antisense compounds and methods for treating, preventing, or ameliorating hypercholesterolemia and/or atherosclerosis. Further disclosed are antisense compounds and methods for decreasing coronary heart disease risk. Such methods include administering to an individual in need of treatment an antisense compound targeted to a PCSK9 nucleic acid. The antisense compounds administered include gapmer antisense oligonucleotides.
    Type: Grant
    Filed: June 4, 2009
    Date of Patent: January 10, 2012
    Assignee: Isis Pharmaceuticals, Inc.
    Inventors: Susan M. Freier, Rosanne M. Crooke, Mark J. Graham, Kristina L. Lemonidis, Sanjay Bhanot, Diane Tribble, Andrew T. Watt
  • Antisense modulation of C-reactive protein expression
    Patent number: 8093224
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of C-reactive protein. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding C-reactive protein. Methods of using these compounds for modulation of C-reactive protein expression and for treatment of diseases associated with expression of C-reactive protein are provided.
    Type: Grant
    Filed: February 1, 2011
    Date of Patent: January 10, 2012
    Assignee: Isis Pharmaceuticals, Inc.
    Inventors: Rosanne M. Crooke, Mark J. Graham
  • SNPs of Apolipoprotein B and Modulation of Their Expression
    Publication number: 20110319469
    Abstract: Compounds, compositions and methods are provided for modulating the expression of apolipoprotein B. The compositions comprise oligonucleotides, targeted to nucleic acid encoding apolipoprotein B. Methods of using these compounds for modulation of apolipoprotein B expression and for diagnosis and treatment of diseases and conditions associated with expression of apolipoprotein B are provided.
    Type: Application
    Filed: January 28, 2011
    Publication date: December 29, 2011
    Applicant: Genzyme Corporation
    Inventors: Rosanne M. Crooke, Mark J. Graham, Steven Mah
  • Methods for treating hypercholesterolemia
    Patent number: 8084437
    Abstract: Disclosed herein are antisense compounds and methods for decreasing LDL-C in an individual having elevated LDL-C. Additionally disclosed are antisense compounds and methods for treating hypercholesterolemia, or alternatively for treating or preventing atherosclerosis. Further disclosed are antisense compounds and methods for decreasing coronary heart disease risk. Such methods include administering to an individual in need of treatment an antisense compound targeted to a PCSK9 nucleic acid. The antisense compounds administered include gapmer antisense oligonucleotides.
    Type: Grant
    Filed: November 27, 2007
    Date of Patent: December 27, 2011
    Assignee: Isis Pharmaceuticals, Inc.
    Inventors: Susan M. Freier, Rosanne M. Crooke, Mark J. Graham, Kristina M. Lemonidis, Sanjay Bhanot, Diane Tribble, Andrew T. Watt
  • MODULATION OF C-REACTIVE PROTEIN EXPRESSION
    Publication number: 20110230544
    Abstract: Compounds, compositions and methods are provided for modulating the expression of C-reactive protein. The compositions comprise oligonucleotides, targeted to nucleic acid encoding C-reactive protein. Methods of using these compounds for modulation of C-reactive protein expression and for diagnosis and treatment of disease associated with expression of C-reactive protein are provided.
    Type: Application
    Filed: October 11, 2010
    Publication date: September 22, 2011
    Applicant: Isis Pharmaceuticals, Inc.
    Inventors: Rosanne M. Crooke, Mark J. Graham
  • ANTISENSE MODULATION OF C-REACTIVE PROTEIN EXPRESSION
    Publication number: 20110117646
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of C-reactive protein. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding C-reactive protein. Methods of using these compounds for modulation of C-reactive protein expression and for treatment of diseases associated with expression of C-reactive protein are provided.
    Type: Application
    Filed: February 1, 2011
    Publication date: May 19, 2011
    Applicant: Isis Pharmaceuticals, Inc.
    Inventors: Rosanne M. Crooke, Mark J. Graham
  • Antisense modulation of C-reactive protein expression
    Patent number: 7915231
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of C-reactive protein. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding C-reactive protein. Methods of using these compounds for modulation of C-reactive protein expression and for treatment of diseases associated with expression of C-reactive protein are provided.
    Type: Grant
    Filed: January 12, 2009
    Date of Patent: March 29, 2011
    Assignee: Isis Pharmaceuticals, Inc.
    Inventors: Rosanne M. Crooke, Mark J. Graham
  • MODULATION OF APOLIPOPROTEIN C-III EXPRESSION
    Publication number: 20110060030
    Abstract: Compounds, compositions and methods are provided for modulating the expression of apolipoprotein C-III. The compositions comprise oligonucleotides, targeted to nucleic acid encoding apolipoprotein C-III.
    Type: Application
    Filed: May 17, 2010
    Publication date: March 10, 2011
    Applicant: Isis Pharmaceuticals, Inc.
    Inventors: Rosanne M. Crooke, Mark J. Graham, Kristina M. Lemonidis, Kenneth W. Dobie
  • MODULATION OF APOLIPOPROTEIN (A) EXPRESSION
    Publication number: 20110039910
    Abstract: Compounds, compositions and methods are provided for modulating the expression of apolipoprotein(a). The compositions comprise oligonucleotides, targeted to nucleic acid encoding apolipoprotein(a). Methods of using these compounds for modulation of apolipoprotein(a) expression and for diagnosis and treatment of disease associated with expression of apolipoprotein(a) are provided.
    Type: Application
    Filed: March 17, 2010
    Publication date: February 17, 2011
    Applicant: Isis Pharmaceuticals, Inc.
    Inventors: Rosanne M. Crooke, Mark J. Graham
  • Antisense modulation of apolipoprotein B expression
    Patent number: 7888324
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of apolipoprotein B. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding apolipoprotein B. Methods of using these compounds for modulation of apolipoprotein B expression and for treatment of diseases associated with expression of apolipoprotein B are provided.
    Type: Grant
    Filed: August 1, 2001
    Date of Patent: February 15, 2011
    Assignee: Genzyme Corporation
    Inventors: Rosanne M. Crooke, Mark J. Graham
  • Modulation of C-reactive protein expression
    Patent number: 7863252
    Abstract: Compounds, compositions and methods are provided for modulating the expression of C-reactive protein. The compositions comprise oligonucleotides, targeted to nucleic acid encoding C-reactive protein. Methods of using these compounds for modulation of C-reactive protein expression and for diagnosis and treatment of disease associated with expression of C-reactive protein are provided.
    Type: Grant
    Filed: January 3, 2008
    Date of Patent: January 4, 2011
    Assignee: Isis Pharmaceuticals, Inc.
    Inventors: Rosanne M. Crooke, Mark J. Graham
  • EFFECTS OF APOLIPOPROTEIN B INHIBITION ON GENE EXPRESSION PROFILES IN ANIMALS
    Publication number: 20100331390
    Abstract: Methods are provided for modulating the expression of genes involved in lipid metabolism, useful in the treatment of conditions associated with cardiovascular risk. Antisense oligonucleotides targeted to apolipoprotein B reduce the level of apolipoprotein B mRNA, lower serum cholesterol and shift liver gene expression profiles from those of an obese animal towards those of a lean animal. Further provided are methods for improving the cardiovascular risk of a subject through antisense inhibition of apolipoprotein B. Also provided are methods for employing antisense oligonucleotides targeted to apolipoprotein B to modulate a cellular pathway or metabolic process.
    Type: Application
    Filed: March 9, 2010
    Publication date: December 30, 2010
    Applicant: Genzyme Corporation
    Inventors: Rosanne M. Crooke, Mark J. Graham
  • MODULATION OF APOLIPOPROTEIN (a) EXPRESSION
    Publication number: 20100273860
    Abstract: Compounds, compositions and methods are provided for modulating the expression of apolipoprotein(a). The compositions comprise oligonucleotides, targeted to nucleic acid encoding apolipoprotein(a). Methods of using these compounds for modulation of apolipoprotein(a) expression and for diagnosis and treatment of disease associated with expression of apolipoprotein(a) are provided.
    Type: Application
    Filed: April 22, 2010
    Publication date: October 28, 2010
    Inventors: Rosanne M. Crooke, Mark J. Graham
  • Antisense modulation of apolipoprotein B-expression
    Patent number: 7803930
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of apolipoprotein B. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding apolipoprotein B. Methods of using these compounds for modulation of apolipoprotein B expression and for treatment of diseases associated with expression of apolipoprotein B are provided.
    Type: Grant
    Filed: August 17, 2004
    Date of Patent: September 28, 2010
    Assignee: Isis Pharmaceuticals, Inc.
    Inventors: Rosanne M. Crooke, Mark J. Graham, Susan M. Freier
  • ANTISENSE MODULATION OF ACYL COA CHOLESTEROL ACYLTRANSFERASE-2 EXPRESSION
    Publication number: 20100197764
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of acyl CoA cholesterol acyltransferase-2. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding acyl CoA cholesterol acyltransferase-2. Methods of using these compounds for modulation of acyl CoA cholesterol acyltransferase-2 expression and for treatment of diseases associated with expression of acyl CoA cholesterol acyltransferase-2 are provided.
    Type: Application
    Filed: December 30, 2009
    Publication date: August 5, 2010
    Applicant: Isis Pharmaceuticals, Inc.
    Inventors: Rosanne M. Crooke, Kristina Lemonidis Tarbet, Mark J. Graham
  • Modulation of apolipoprotein c-III expression
    Patent number: 7750141
    Abstract: Compounds, compositions and methods are provided for modulating the expression of apolipoprotein C-III. The compositions comprise oligonucleotides, targeted to nucleic acid encoding apolipoprotein C-III. Methods of using these compounds for modulation of apolipoprotein C-III expression and for diagnosis and treatment of disease associated with expression of apolipoprotein C-III are provided.
    Type: Grant
    Filed: April 15, 2004
    Date of Patent: July 6, 2010
    Assignee: Isis Pharmaceuticals, Inc.
    Inventors: Rosanne M. Crooke, Mark J. Graham, Kenneth W. Dobie
  • Modulation of apolipoprotein (a) expression
    Patent number: 7741305
    Abstract: Compounds, compositions and methods are provided for modulating the expression of apolipoprotein(a). The compositions comprise oligonucleotides, targeted to nucleic acid encoding apolipoprotein(a). Methods of using these compounds for modulation of apolipoprotein(a) expression and for diagnosis and treatment of disease associated with expression of apolipoprotein(a) are provided.
    Type: Grant
    Filed: July 30, 2007
    Date of Patent: June 22, 2010
    Assignee: Isis Pharmaceuticals, Inc.
    Inventors: Rosanne M. Crooke, Mark J. Graham
  • METHODS FOR TREATING HYPERCHOLESTEROLEMIA
    Publication number: 20100144834
    Abstract: Disclosed herein are antisense compounds and methods for decreasing LDL-C in an individual having elevated LDL-C. Additionally disclosed are antisense compounds and methods for treating hypercholesterolemia, or alternatively for treating or preventing atherosclerosis. Further disclosed are antisense compounds and methods for decreasing coronary heart disease risk. Such methods include administering to an individual in need of treatment an antisense compound targeted to a PCSK9 nucleic acid. The antisense compounds administered include gapmer antisense oligonucleotides.
    Type: Application
    Filed: November 27, 2007
    Publication date: June 10, 2010
    Applicant: ISIS PHARMACEUTICALS, INC.
    Inventors: Susan M. Freier, Rosanne M. Crooke, Mark J. Graham, Kristina Lemonidis Tarbet, Sanjay Bhanot, Diane Tribble, Andrew T. Watts
  • Modulation of apolipoprotein (A) expression
    Patent number: 7723508
    Abstract: Compounds, compositions and methods are provided for modulating the expression of apolipoprotein(a). The compositions comprise oligonucleotides, targeted to nucleic acid encoding apolipoprotein(a). Methods of using these compounds for modulation of apolipoprotein(a) expression and for diagnosis and treatment of disease associated with expression of apolipoprotein(a) are provided.
    Type: Grant
    Filed: June 2, 2004
    Date of Patent: May 25, 2010
    Assignee: Isis Pharmaceuticals, Inc.
    Inventors: Rosanne M. Crooke, Mark J. Graham